NASDAQ:TRIB - Trinity Biotech Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.00
▼ -0.05 (-2.44%)

This chart shows the closing price for TRIB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Trinity Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRIB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRIB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Trinity Biotech in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.00.

This chart shows the closing price for TRIB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Trinity Biotech. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/5/2016StephensDowngradeOverweight ➝ Equal WeightN/A
(Data available from 7/25/2016 forward)
Trinity Biotech logo
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Read More

Today's Range

Now: $2.00
Low: $1.90
High: $2.09

50 Day Range

MA: $2.87
Low: $1.82
High: $3.70

52 Week Range

Now: $2.00
Low: $1.57
High: $6.82

Volume

246,884 shs

Average Volume

224,297 shs

Market Capitalization

$41.80 million

P/E Ratio

16.67

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Trinity Biotech?

The following Wall Street sell-side analysts have issued stock ratings on Trinity Biotech in the last twelve months: TheStreet.
View the latest analyst ratings for TRIB.

What is the current price target for Trinity Biotech?

0 Wall Street analysts have set twelve-month price targets for Trinity Biotech in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Trinity Biotech in the next year.
View the latest price targets for TRIB.

What is the current consensus analyst rating for Trinity Biotech?

Trinity Biotech currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TRIB.

What other companies compete with Trinity Biotech?

How do I contact Trinity Biotech's investor relations team?

Trinity Biotech's physical mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The company's listed phone number is 353-1276-9800 and its investor relations email address is [email protected] The official website for Trinity Biotech is www.trinitybiotech.com.